NSC59984|NSC-59984|cas 803647-40-7

Cas No.:	803647-40-7
Chemical Name:	NSC-59984,NSC 59984
Synonyms:	NSC-59984,NSC 59984
SMILES:	CN1CCN(CC1)C(=O)/C=C/C2=CC=C(O2)[N+](=O)[O-]
Formula:	C₁₂H₁₅N₃O₄
M.Wt:	265.27
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway. The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells.
In Vivo:	NSC59984 synergizes with CPT11 to induce cell death in mutant p53-expressing colorectal cancer cells and inhibits mutant p53-associated colon tumor xenograft growth in a p73-dependent manner.
In Vitro:	NSC59984 specifically restores p53 pathway signaling in mutant p53-expressing human colorectal cancer cells. NSC59984 induces cell death in tumor cells but not normal cells with little or no genotoxicity. NSC59984 induces mutant p53 protein degradation through MDM2-mediated ubiquitination in cancer cells. NSC59984 restores p53 pathway signaling through activation of p73. NSC59984 induces p73-dependent cell apoptosis in cancer.

Cat. No.	Product name	Field of application
DC10851	PK11000	PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 by covalent cysteine modification, without compromising DNA binding.
DC9504	YH239-EE	YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent
DC7314	Tenovin-3	Tenovin-3 is a small molecule activator of p53 transcriptional activity.
DC8467	RO8994	RO8994 is a potent and selective spiroindolinone MDM2 inhibitor for cancer therapy.
DC8865	RG-7112	RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor.
DC10070	PRIMA-1MET(APR-246)	PRIMA-1MET is methylated derivative of PRIMA-1. It can restore mutant p53 activity.
DC9902	PRIMA-1	PRIMA-1 is a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
DC9257	NSC59984	NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway.The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells.
DC10074	MX69	MX69 is the MDM2/XIAP inhibitor, used for cancer treatment.
DC8414	MI-77301 (SAR405838)	MI-77301 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.